Late last month, BBK hosted the webinar Rare Disease 20/20: A Look at the Challenges and Opportunities in Rare Disease Clinical R&D giving our listeners the opportunity to gain insights from thought leaders in rare disease patient advocacy and orphan drug development.
BBK Worldwide is very excited to be participating in the Cambridge Health Institute’s 7th Annual SCOPE Summit for Clinical Ops Executives. Taking place February 23 – 25 in Miami FL, SCOPE will offer three days of in-depth discussions addressing the operational, technological and data-related aspects of clinical trial planning and management, with 12 different conferences, 4 pre-conference workshops and 2 symposia.
To raise awareness with policy makers and the public of rare diseases and of their impact on the lives of patients and their loved ones, the National Organization for Rare Disorders (NORD) established Rare Disease Day® in the U.S. almost seven years ago. Since then, people all over the world have come together to inform the public and engage with policy makers, researchers, health professionals and more, affecting positive change for all those impacted by rare diseases.
It has become clear that you cannot discuss the future of global clinical research and its innovations without talking about South Korea. In our previous blog post, we delved into South Korea’s clinical research infrastructure, and found that it is among the best-equipped countries in the world for hosting clinical trials – with substantial governmental support, joint IRBs, and streamlined drug application and approval processes. In the second half of this series, we will discuss the prevalence of mobile health solutions in South Korea to determine what aspects of BBK’s mobile health initiatives resonate most with the population.
Today’s post will feature insights from our strategic global alliance partner at Inje Paik Clinical Trial Center in South Korea. Pioneers of the clinical R&D industry in the region, Inje Paik is transforming the clinical research study groundwork through innovative initiatives and programs, exclusive and robust investigator and patient networks, and creative strategies and technologies.
Active international collaboration has facilitated the rise of the Asia Pacific region in global clinical research. In the first two parts of this blog series, we’ve discussed how Japan and South Korea – whose clinical research environments vary significantly from each other – share many common interests in their pursuit for advancing clinical R&D. The open flow of data between these countries, and their desire for expanding research, has resulted in a dynamic climate for conducting clinical trials.
Japan has taken significant steps in establishing itself as a major player in the global clinical research community, driving the demand for more clinical trials across East Asia as a result. By officially acknowledging and seeking clinical data from the Asia Pacific region, Japan is facilitating a dialogue with one of the most powerful and capable clinical trial landscapes in the world: South Korea.
On the heels of our recent post on our presence at this week’s DIA Japan 2015, BBK welcomes Philip Gregory, the General Manager of George Clinical - CRO China as our guest contributor. With more than 20 years of experience in pharmaceutical, biotech and medical device marketing, Mr. Gregory has spent over 14 years supporting the expansion of clinical trial capabilities in Asia. He will be providing his insights over the course of a three-part blog series on the growth of clinical research across the Asia Pacific region.
We are very excited to be attending next week’s 12th Annual Meeting DIA Japan 2015, to be held at Tokyo Big Sight in Tokyo, November 15 – 17. It’s the first time that many of us based here in our U.S. headquarters will be joining our Japan team since opening our new Tokyo office over the summer. Under the theme “Medicine Development” this year’s event is set to focus on the innovative and constructive influence of patients on the enterprise of clinical R&D – a topic that’s always at the center of our work here at BBK.
Choosing the right countries and sites for a particular study remains one of the industry’s biggest challenges – but it doesn’t have to be. When the time comes to select sites for your clinical research study, there are many considerations that can guide your decisions to ensure the best possible outcome.
Topics: Site Selection